[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369110-105":59,"doc-detail-369110-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","resistance-mechanisms-to-immune-checkpoint-inhibitors-updated-insights","Resistance mechanisms to immune checkpoint inhibitors: updated insights","","The last decade has seen major successes with immune checkpoint inhibitors in cancer therapy, yet only a limited fraction of patients achieve favorable outcomes. Treatment resistance—either primary or acquired after an initial response—limits clinical effectiveness and drives ongoing mechanistic research. This review consolidates current knowledge by organizing resistance pathways around tumor-intrinsic and tumor-extrinsic factors, emphasizing multimodal cross-talk between tumor cells, the immune compartment, and other host-related influences.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/resistance-mechanisms-to-immune-checkpoint-inhibitors-updated-insights/369110/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/resistance-mechanisms-to-immune-checkpoint-inhibitors-updated-insights/369110.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem limits the effectiveness of immune checkpoint inhibitors in cancer treatment?","Question",{"text":113,"@type":114},"A relatively modest proportion of patients respond favorably, largely because of treatment resistance. Resistance may occur as primary resistance or develop after an initial response.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the review classify resistance mechanisms to immune checkpoint inhibitors?",{"text":118,"@type":114},"It organizes mechanisms as tumor-intrinsic versus tumor-extrinsic. This classification accounts for multimodal interactions among tumor cells, the immune system compartment, and other host-related factors.",{"name":120,"@type":111,"acceptedAnswer":121},"Which immune checkpoint molecules do immune checkpoint inhibitors target?",{"text":122,"@type":114},"Immune checkpoint inhibitors are described as monoclonal antibodies targeting inhibitory molecules such as PD-1, PD-L1, and CTLA-4 to reinvigorate anti-tumor immune responses.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369110,1790293388,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Alsaafeen et al. Molecular Cancer (2025) 24:20 [https://doi.org/10.1186/s12943-024-02212-7](https://doi.org/10.1186/s12943-024-02212-7)  \nMolecular Cancer  \n REVIEW Open Access  \nResistance mechanisms to immune checkpoint inhibitors: updated insights  \nBesan H. Alsaafeen 1,2, Bassam R. Ali 1,2* and Eyad Elkord3,4,5*  \nAbstract  \nThe last decade has witnessed unprecedented succusses with the use of immune checkpoint inhibitors in treating cancer. Nevertheless, the proportion of patients who respond favorably to the treatment remained rather modest, partially due to treatment resistance. This has fueled a wave of research into potential mechanisms of resistance to immune checkpoint inhibitors which can be classified into primary resistance or acquired resistance after an initial response. In the current review, we summarize what is known so far about the mechanisms of resistance in terms of being tumor-intrinsic or tumor-extrinsic taking into account the multimodal crosstalk between the tumor, immune system compartment and other host-related factors.  \nKeywords Immune checkpoint inhibitors, Resistance, Tumor-intrinsic, Tumor-extrinsic  \nIntroduction  \nCancer is a major global public health burden and a leading cause of death worldwide with a recorded 19.3 million new cases and 10 million deaths each year [1, 2]. In the clinical settings, conventional cancer treatment modalities including chemotherapy and radiotherapy have been associated with inherent limitations such as lack of tumor specificity, poor tumor tissue penetration, chances of recurrence and systemic toxicities. Therefore,  \n*Correspondence: Bassam R. Ali [bassam.ali@uaeu.ac.ae](bassam.ali@uaeu.ac.ae)[ ](bassam.ali@uaeu.ac.ae)Eyad Elkord [Eyad.Elkord@xjtlu.edu.cn](Eyad.Elkord@xjtlu.edu.cn)  \n1 Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, P. O. Box: 15551, Al-Ain, United Arab Emirates  \n2 ASPIRE Precision Medicine Research Institute Abu Dhabi, United Arab Emirates University, Al Ain, United Arab Emirates  \n3 Department of Biosciences and Bioinformatics & Suzhou Municipal Key Lab of Biomedical Sciences and Translational Immunology, School of Science, Xi’an Jiaotong-Liverpool University, Suzhou, China  \n4 College of Health Sciences, Abu Dhabi University, Abu Dhabi, United Arab Emirates  \n5 Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manchester, UK  \nthese limitations interfered with achieving beneficial therapeutic outcomes for most patients and highlighted the need to improve the strategies and modalities of cancer treatment.  \nAfter significant and concerted efforts and investigation, the critical roles of the immune system in controlling tumor development and progression have been established. This led to the emergence of immunotherapy as a new and promising modality to treat cancer. The increased understanding of immunosurveillance and the complex crosstalk between tumor cells and immune system compartment along with the development of molecular biology have nourished the field of cancer immunotherapy. Over the past decade, the emergence of immunotherapy has changed the paradigm of cancer treatment from the direct killing of cancerous cells to empowering the anti-tumor immune responses, and therefore is considered one of the most appealing and flourishing cancer treatment modalities of recent years [3]. Nowadays, several immunotherapeutic approaches, including immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy and cancer vaccines have been designed and implemented in the clinical use to treat a wide-spectrum of malignancies.  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit t","cbCaioLKzmYMQixu","https://ap.wps.com/l/cbCaioLKzmYMQixu","pdf",2530902,"English","# Abstract\n# Introduction\n## Immune checkpoint inhibitors in cancer therapy\n## Resistance mechanisms: primary vs acquired\n## Tumor-intrinsic and tumor-extrinsic pathways","[{\"question\":\"What problem limits the effectiveness of immune checkpoint inhibitors in cancer treatment?\",\"answer\":\"A relatively modest proportion of patients respond favorably, largely because of treatment resistance. Resistance may occur as primary resistance or develop after an initial response.\"},{\"question\":\"How does the review classify resistance mechanisms to immune checkpoint inhibitors?\",\"answer\":\"It organizes mechanisms as tumor-intrinsic versus tumor-extrinsic. This classification accounts for multimodal interactions among tumor cells, the immune system compartment, and other host-related factors.\"},{\"question\":\"Which immune checkpoint molecules do immune checkpoint inhibitors target?\",\"answer\":\"Immune checkpoint inhibitors are described as monoclonal antibodies targeting inhibitory molecules such as PD-1, PD-L1, and CTLA-4 to reinvigorate anti-tumor immune responses.\"}]","Resistance mechanisms to immune checkpoint inhibitors: updated insights | PDF",1790180817,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3d243270919bf7a79863256c632854f.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df68852789498c1f37c5b49c57b7f401.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a04c0df2409cbc960c379b0484cab9b6.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebdbcd5de5c62794733d94711a38e3d0.webp",980,1301]